Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02817100

First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080

Clinical Trials, Phase I as Topic Clinical Trial

Official title:
Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (10 - 1500 mg, Tablets) of BAY1817080 Including the Effect of Food and Itraconazole on the Relative Bioavailability of BAY1817080 in Healthy Men

Clinical Trial Summary

This study is a first in human study that will investigate the safety, tolerability and pharmacokinetics of ascending single doses of BAY1817080 using a placebo controlled, randomized, single center design. In addition the influence of itraconazole and food on the pharmacokinetics of BAY1817080 will be investigated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Clinical Trials, Phase I as Topic
Clinical Trial Details
NCT number NCT02817100
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date July 22, 2016
Completion date August 23, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT02212080 - First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784 Phase 1
Completed NCT03212586 - BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect Phase 1